Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

This was the stock's third consecutive day of losses.

The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol-Myers Squibb Company (NYSE:BMY) had been left for dead on Wall Street, plagued by years of missed earnings and patent ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Bristol Myers Squibb will cut $2 billion in costs by the end of 2027, a move aimed at long-term growth as the company prepares for patent expirations on key treatments, CNBC reported Feb. 6.

Equities research analysts at William Blair decreased their FY2026 earnings per share estimates for shares of Bristol-Myers ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...